Eledon Pharmaceuticals to Participate in 18th Annual Noble Capital Markets Investor Conference
April 18, 2022 16:05 ET
|
Eledon Pharmaceuticals, Inc.
IRVINE, Calif., April 18, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a patient-focused clinical stage biopharmaceutical company committed to the development of...
Eledon to Host Virtual R&D Day on Thursday, April 28, 2022
April 14, 2022 16:05 ET
|
Eledon Pharmaceuticals, Inc.
IRVINE, Calif., April 14, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a patient-focused clinical stage biopharmaceutical company committed to the development of...
Eledon Pharmaceuticals Reports Fourth Quarter and Full-Year 2021 Operating and Financial Results
March 24, 2022 16:01 ET
|
Eledon Pharmaceuticals, Inc.
Topline data from Phase 2a trial of tegoprubart in ALS expected in 2Q 2022 Ongoing clinical studies evaluating tegoprubart in kidney transplantation, IgA nephropathy, and islet cell transplantation...
Eledon Pharmaceuticals to Report Fourth Quarter and Full Year 2021 Financial Results on Thursday, March 24, 2022
March 17, 2022 08:00 ET
|
Eledon Pharmaceuticals, Inc.
IRVINE, Calif., March 17, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a patient-focused clinical stage biopharmaceutical company committed to the development of...
Eledon Pharmaceuticals Provides Corporate Update and 2022 Outlook
February 14, 2022 08:00 ET
|
Eledon Pharmaceuticals, Inc.
Completed enrollment of all four cohorts in ongoing Phase 2a study with tegoprubart (AT-1501) in Amyotrophic Lateral Sclerosis (ALS) Announces USAN Approval of Generic Name “tegoprubart” for lead...
Eledon Pharmaceuticals to Participate in 11th Annual SVB Leerink Global Healthcare Conference
February 08, 2022 16:05 ET
|
Eledon Pharmaceuticals, Inc.
IRVINE, Calif., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a patient-focused clinical stage biopharmaceutical company committed to the development of...
Orgenesis to Present at the 2017 Marcum MicroCap Conference
June 12, 2017 08:00 ET
|
Orgenesis Inc.
GERMANTOWN, MD--(Marketwired - Jun 12, 2017) - Orgenesis Inc. (OTCQB: ORGS), a vertically-integrated biopharmaceutical company with expertise and unique experience in cell therapy development and...
Orgenesis Provides Update Regarding AIP Cell-Based Therapy for Type 1 Diabetes, MaSTherCell Cell Manufacturing Subsidiary and Overall Financial Condition
March 08, 2017 09:00 ET
|
Orgenesis Inc.
GERMANTOWN, MD--(Marketwired - Mar 8, 2017) - Orgenesis Inc. (OTCQB: ORGS), a vertically-integrated biopharmaceutical company with expertise and unique experience in cell therapy development and...
Orgenesis Approved for Euro 12.3 Million European Grant for Further Development of Its Type 1 Diabetes Program
February 13, 2017 08:30 ET
|
Orgenesis Inc.
GERMANTOWN, MD--(Marketwired - Feb 13, 2017) - Orgenesis Inc. (OTCQB: ORGS), a fully-integrated cell therapy and contract development and manufacturing company, announced that its Belgian...
Servier Appoints MaSTherCell for the Development of its CAR-T Cell Therapy Manufacturing Platform
January 20, 2017 09:00 ET
|
Orgenesis Inc.
GERMANTOWN, MD--(Marketwired - Jan 20, 2017) - Orgenesis Inc. (OTCQB: ORGS), a fully-integrated cell therapy and contract development and manufacturing company, announced that its...